United States securities and exchange commission logo





                          April 24, 2024

       Samuel Kintz
       Chief Executive Officer
       Enliven Therapeutics, Inc.
       6200 Lookout Road
       Boulder, CO 80301

                                                        Re: Enliven
Therapeutics, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed April 18,
2024
                                                            File No. 333-278801

       Dear Samuel Kintz:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Doris
Stacey Gama at 202-551-3188 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Rachel Nagashima, Esq.